Harmony Biosciences Holdings Inc
Suletud
SektorTervishoid
41.21 0.37
Ülevaade
Aktsiahinna muutus
24h
Min
40.65
Max
41.67
Sissetulek | 43M 75M |
|---|---|
Müük | 46M 261M |
P/E Sektori keskmine | 13.673 56.597 |
Aktsiakasum | 1.28 |
Kasumimarginaal | 28.87 |
Töötajad | 293 |
EBITDA | 53M 102M |
Järgmine tulemuste avaldamine | 3. nov 2026 |
|---|
Turukapital | 400M 2.5B |
|---|---|
Eelmine avamishind | 40.84 |
Eelmine sulgemishind | 41.21 |
Uudiste sentiment
By Acuity
67%
33%
289 / 339 Pingereas Healthcare
Harmony Biosciences Holdings Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Harmony Biosciences Holdings Inc Prognoos
Sentiment
By Acuity
289 / 339 Pingereas Tervishoid
Uudiste sentiment
Tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.